



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |  |  |                        |
|---|--|--|--|------------------------|
| (51) International Patent Classification <sup>6</sup> : |  | A1   | (11) International Publication Number: | WO 96/14064            |
| A61K 31/35  |  |  | (43) International Publication Date:   | 17 May 1996 (17.05.96) |
| (21) International Application Number:                  |  | PCT/US95/14056   |  |                        |
| (22) International Filing Date:                         |  | 3 November 1995 (03.11.95)   |  |                        |
| (30) Priority Data:                                     |  | 08/335,138   | 7 November 1994 (07.11.94)             | US                     |
| (71) Applicant:   |  | STRECKER, Robert, B. [US/US]; 1501 Colorado Boulevard, Eagle Rock, CA 90041 (US).  |  |                        |
| (71)(72) Applicant and Inventor:                        |  | FREDRICKSON, William, R. [US/US]; 5461 North Illinois Street, Indianapolis, IN 46208 (US).   |  |                        |
| (74) Agent:   |  | LAMMERT, Steven, R.; Barnes & Thornburg, 1313 Merchants Bank Building, 11 South Meridian Street, Indianapolis, IN 46204 (US).  |  |                        |
| (81) Designated States:                                 |  | AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). |  |                        |
| Published   |  | With international search report.  |  |                        |

(54) Title: METHOD AND COMPOSITION FOR ANTIVIRAL THERAPY

## (57) Abstract

A method of treatment of diseases of viral origin is disclosed. The method comprises oral or parenteral administration of an antiviral amount of a naturally occurring secoiridoid from plants of the family *Oleaceae* or derivatives thereof. Preferred oral dosage forms include the secoiridoid oleuropein in pure form or as a component of dried plant material of *Olea europaea* or a dried extract thereof and a pharmaceutically acceptable carrier.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                           | MR | Mauritania               |
| AU | Australia                | GE | Georgia                                  | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                   | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                   | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                                  | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                                  | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                    | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                    | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                    | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                               | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                        | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                               | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LJ | Liechtenstein                            | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                                | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                               | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                   | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                   | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                      | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                               | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                     | US | United States of America |
| FI | Finland                  | MN | Mongolia                                 | UZ | Uzbekistan               |
| FR | France                   |    |  | VN | Viet Nam                 |
| GA | Gabon                    |    |  |    |                          |

-1-


METHOD AND COMPOSITION FOR ANTIVIRAL THERAPY

Field of the Invention

This invention relates to treatment of disease  
5 of viral origin in warm-blooded vertebrates. More particularly, this invention is directed to the use of secoiridoid compounds naturally occurring in plants of the family Oleaceae and derivatives thereof.

10 Background and Summary of the Invention

The olive tree and other members of the Family Oleaceae have been documented as a source of medicinal substances since biblical times. Needless to say, many researchers have studied the cocktail of phytogenic 15 substances produced by the olive and other members of the Family Oleaceae. One compound that has received attention from the research community is the secoiridoid glucoside oleuropein, a compound of the formula



wherein R is glycosyl and R<sub>1</sub> is 2-(3,4-dihydroxyphenyl) ethyl. Related secoiridoids wherein R<sub>1</sub> is H, CH<sub>3</sub> or 2-(4-hydroxyphenyl ethyl) are also known to be endogenous to many plant species of the family Oleaceae, although in lesser concentrations and in fewer identified species than the ubiquitous oleuropein.


30 Animal studies have revealed that oleuropein itself or as a component of extracts of plant tissues containing that compound exhibit both hypoglycemic and cardiovascular effects. It is also known that oleuropein  
35

-2-

can be acid hydrolyzed to produce (-)-elenolic acid, a compound which has been reported to have antiviral properties *in vitro*, but little, if any, activity *in vivo*.

5       The present invention is based on the discovery that secoiridoid glucosides of the formula

10




15

wherein R is glycosyl and R<sub>1</sub> is hydrogen or an ester-forming group are metabolized *in vivo* to the dextrorotatory form of elenolic acid [(+)-elenolic acid], a compound of the formula


20

25




30       wherein R<sub>1</sub> is hydrogen, a compound which is believed to be more available *in vivo* than the corresponding diasteromer (-)-elenolic acid of the formula

-3-



The enhanced *in vivo* efficacy of the oleuropein metabolite, (+)-elenolic acid relative to the corresponding levorotatory compound is thought to be due,  
 10 at least in part, to its reduced affinity for serum proteins and thus its greater availability for uptake by virus infected tissues. Antivirally effective blood levels of (+)-elenolic acid can also be achieved by administration of (+)-elenolic acid and its esters of the  
 15 formula



25

wherein R<sub>1</sub> is hydrogen or a pharmaceutically acceptable ester-forming group and salts thereof, which can be prepared from secoiridoid glucosides naturally occurring in plant material of the family Oleaceae via extraction and controlled enzyme (glucosidase) hydrolysis and/or deesterification/transesterification reactions.

Thus, it is one object of the present invention to provide a method of treatment of disease of viral origin in warm-blooded vertebrates by administering

-4-

antiviral compositions containing secoiridoid glucosides native to the plant family Oleaceae and derivatives thereof.


Another object of the invention is to provide  
5 oral dosage forms of secoiridoid glucosides of *Olea europaea* and derivatives thereof.

In another more particular aspect of this invention plant material of the family Oleaceae and extracts thereof containing naturally occurring  
10 oleuropein glucosides and enzyme hydrolysates thereof are administered in treatment of diseases of viral origin in warm-blooded vertebrates suffering from such diseases.

One further object of this invention is a method for establishing antivirally effective blood  
15 levels of (+)-elenolic acid by the administration of oleuropein glucosides native to the family Oleaceae or their derivatives via transesterification, diesterification and/or glucolysis.

20 Detailed Description of the Invention

The present invention is directed to a method of treatment of disease of viral origin in warm-blooded vertebrates and to pharmaceutical formulations for use in such treatment methods. The method comprises the step of  
25 administering to a vertebrate suffering from a disease of viral origin an antivirally effective amount of an antiviral composition comprising a compound of the formula



-5-

and a pharmaceutically acceptable carrier therefor. In the above formula, the group R is glucosyl and R<sub>1</sub> is hydrogen or a pharmaceutically acceptable ester-forming group. When R<sub>1</sub> is hydrogen, the acid compound represented  
5 can be utilized in the form of one of its pharmaceutically acceptable salts.

There are many diseases of viral etiology that afflict man and animal. In man, diseases such as hepatitis, mononucleosis, shingles, herpes, influenza,  
10 the common cold and even certain types of leukemia are known to be of viral etiology. Viral infections are also common in many animal species, both in meat producing and in companion animals. Rotavirus infections plague swine. Cattle develop bovine rhinovirus infections (shipping  
15 fever) when subjected to conditions of stress. Canine parvovirus and feline leukemia virus are common viral infections in those companion animals species. Such diseases of viral origin can be treated with resultant reduction in clinical symptomology by therapeutic  
20 administration of antiviral compositions in accordance with this invention.

The antiviral compositions administered in accordance with this invention comprise a compound of Formula I or II above in combination with a pharmaceutically acceptable carrier. The compounds of  
25 Formula I wherein R<sub>1</sub> is 2-(4-hydroxyphenyl)ethyl or 2-(3,4-dihydroxyphenyl)ethyl are naturally occurring compounds in many plants of the Family Oleaceae, including members of the genus *Fraxinus*, *Syringa* and the  
30 genus *Ligustrum*. Preferred plant sources of the naturally occurring secoiridoids of Formula I wherein R<sub>1</sub> is 2-(4-hydroxyphenyl)ethyl and 2-(3,4-dihydroxyphenyl)ethyl are varieties of *Olea europaea* (the olive). Preferred varieties of *Olea europaea* as a source

-6-

of secoiridoid glycosides for use in accordance with this invention are the varieties Manzanillo and Mission.

The most prevalent of the secoiridoid compounds in such varieties is the compound of Formula I wherein R<sub>1</sub> 5 is 2-(3,4-dihydroxyphenyl)ethyl and R is glucosyl, a compound given the common name oleuropein. That compound can be readily isolated from plant material, preferably ground leaves of the olive by aqueous or aqueous-alcoholic extraction at room temperature or above, 10 preferably at elevated temperature of about 40 to about 100°C.

Oleuropein can then be purified, for example, by chromatographic separation procedures. That compound can then be used to formulate antiviral compositions in 15 accordance with this invention or to prepare other antivirally effective compounds represented by Formulas I or II. Thus, for example, oleuropein can be subjected, to base catalyzed transesterification wherein the R<sub>1</sub> group 2-(3,4-dihydroxyphenyl)ethyl is exchanged with another 20 pharmaceutically acceptable ester-forming group. The term "pharmaceutically acceptable ester-forming group" as used in defining the present invention, refers to those ester-forming groups which when cleaved via esterase reactions *in vivo* produce substantially non-toxic, 25 physiologically compatible alcohols. Suitable pharmaceutically acceptable ester-forming groups include C<sub>1</sub>-C<sub>4</sub> lower alkyl, and substituted C<sub>1</sub>-C<sub>4</sub> alkyl, benzyl, substituted benzyl wherein the substituents are halo, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, and the like. The compound of 30 Formula I wherein R<sub>1</sub> is hydrogen can be produced by esterase-mediated deesterification of oleuropein, typically in an aqueous medium at a pH between about 6 and about 8.5.

The compounds of Formula II are prepared from 35 the corresponding compounds of Formula I by treatment

-7-

with glucosidase, preferably that from the olive at a pH of about 4 to about 5. The compound of Formula II wherein R<sub>1</sub> is hydrogen is (+)-elenolic acid.

The compounds of Formula I or II wherein R<sub>1</sub> is hydrogen represent carboxylic acids and such acids can be used in accordance with this invention in the acid form or in the form of their pharmaceutically acceptable salts formed with organic bases or inorganic bases, such as ammonium, alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Bases useful in preparing such salts include sodium hydroxide, potassium hydroxide, ammonium hydroxide, and potassium carbonate. Of the salt forms, the potassium and sodium salts are particularly preferred.

The antiviral compositions of the present invention can be administered orally or parenterally in an antivirally effective amount to treat, i.e., reduce the symptoms, of diseases of viral origin. Oral dosage forms can be in a solid or liquid form and comprise an antivirally effective amount of a compound of Formula I or Formula II above and a pharmaceutically acceptable carrier. Such dosage forms can be formulated from pure compounds of Formula I or Formula II, or they can be formulated from ground plant materials of the family Oleaceae, preferably leaves of *Olea europaea*, or aqueous or aqueous alcoholic extracts thereof. Thus, for example, extraction of dried olive leaves with two volumes of a 12-15% ethanol/water solution for 10 days at room temperature provides an extract containing about 70 to about 250 mg of oleuropein per two ounces of the liquid extract. The extract itself can be administered orally as an antiviral composition in accordance with the method of treatment of the present invention, or aqueous or aqueous alcoholic (preferably methanol or ethanol) extracts can be spray-dried to provide a dry powder which

-8-

can be formulated into oral dosage forms with other pharmaceutically acceptable carriers.

The solid oral dosage form compositions in accordance with this invention are prepared in a manner well known in the pharmaceutical art, and comprise at least one compound of Formula I or Formula II associated with at least one pharmaceutically acceptable carrier. In making such compositions, the compound of Formula I or Formula II, either in pure form or as a component of ground plant material or extracts thereof, are usually mixed, diluted or enclosed within a carrier. The carrier can be in a solid form, semi-solid or liquid material which acts as a vehicle, carrier or medium for the active ingredient. Alternatively, the carrier can be in the form of a capsule or other container to facilitate oral administration. Thus the solid oral dosage forms for administration in accordance with the method of this invention can be in the form of tablets, pills, powders or soft or hard gelatin capsules. Alternatively, the antiviral compositions in accordance with this invention for oral administration can be in liquid form wherein the pharmaceutically acceptable carrier is water or an aqueous alcoholic medium. The compositions for administration in the present method can also be formulated with other common pharmaceutically acceptable excipients, including lactose, dextrose, sucrose, sorbitol, mannitol, starches, gums, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, methylcellulose, water, alcohol and the like. The formulations can additionally include lubricating agents such as talc, magnesium stearate and mineral oil, wetting agents, emulsifying and suspending agents, preserving agents such as methyl- and propylhydroxybenzoates, sweetening agents or flavoring agents. Further the compositions of the present invention can be formulated

-9-

so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.


Orally administered compositions are preferably 5 formulated in unit dosage form with each dosage normally containing from about 30 to about 500 mg of a compound of the Formula I or Formula II, more typically about 100 to about 500 mg of such active compounds. The term "unit dosage form" refers to physically discrete units suitable 10 as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical carrier/excipient. The preferred dosage levels of the 15 compounds of Formula I/Formula II for treatment of viral infections in accordance with this invention depend on the route of administration, the nature of the active compound or combination of active compounds, and patient condition. When administered orally for treatment of 20 viral disease, the compounds of Formula I or Formula II are administered at a dose of about 0.1 to about 15 mg/kg, more preferably about 0.2 to about 10 mg/kg of patient/animal body weight. In treatment of viral infections oral dosage forms in accordance with this 25 invention can be administered 1 to 4 times a day, again depending on patient condition and the nature of the disease being treated.

Similar considerations bear on the dosage range 30 for parenteral administration of compounds of Formula I or Formula II in treatment of viral infections in accordance with this invention. Parenteral doses are, however, typically lower than those required for antiviral efficacy via the oral route of administration. Thus, antiviral treatment can be achieved by parenteral 35 administration of about 0.05 to about 3 mg/kg of

-10-

patient/animal body weight. Parenteral formulations for use in accordance with the present invention are prepared using standard techniques in the art. They are commonly prepared as sterile injectable solutions, using a  
 5 parenterally acceptable carrier such as isotonic saline solution or as a sterile packaged powder prepared for reconstitution with sterile buffer or isotonic saline prior to administration to a patient. The injectable formulation can contain from about 1 to 50 mg of a  
 10 compound of Formula I or II per ml of formulation.

Administration of an antivirally effective amount of a composition comprising a compound of Formula I or Formula II and a pharmaceutically acceptable carrier in accordance with this invention produce antivirally  
 15 effective blood levels of (+)-elenolic acid, a compound of the formula



25 via a heretofore unappreciated *in vivo* hydrolysis, and in the case of the compounds of Formula I, stereoselective hydrolysis/rearrangement. Administration of antiviral compositions of a compound of Formula I as part of  
 30 ground/dried native plant material, preferably olive leaves, or as an aqueous or alcoholic extract of olive leaves is a particularly preferred embodiment in accordance with this invention. While not wishing to be bound by theory, the level of antiviral activity  
 35 associated with such antiviral compositions may derive

-11-

from a synergistic antiviral effect with other natural components of the olive leaf, such as the flavonoids rutin, hesperidin, and luteolin-7-glucoside.

The following non-limiting examples are 5 illustrative of the method and compositions of the present invention. It is understood, however, that such examples are but representative of various embodiments of the invention and it is not intended that the invention be limited to the scope of the examples.

10

Example 1

(A) A volume of dried leaves of *Olea europaea* is suspended in 2 volumes of red wine and held at room temperature for about 7 to about 10 days with periodic 15 stirring. Filtration of the mixture provides a tincture containing about 88 mg of oleuropein per ounce of fluid.

(B) A volume of dried leaves of *Olea europaea* is suspended in two volumes of water and the resulting suspension is then subjected to conditions of high shear 20 in a Waring blender to produce a dispersion of finely divided plant material which was held at a temperature of about 40 to about 65° for two days. Filtration of the mixture provides an aqueous extract containing about 72 mg of oleuropein per ounce of fluid. The aqueous extract 25 is optionally blended with effective amounts of sweetening and/or flavoring agents to provide a palatable liquid oral dosage form of oleuropein.

(C) One volume of leaves or buds of *Olea europaea* is combined with about two volumes of a 3:2 30 mixture of methanol and water. The resulting aqueous alcoholic suspension of plant material is heated for 16 hours at about 75°C, cooled and filtered to provide an aqueous alcoholic extract. The extract is spray-dried to produce a powder comprising oleuropein. The powder is

-12-

filled into gelatin capsules in an amount sufficient to provide 30 to about 500 mg of oleuropein per capsule.

(D) The spray-dried extract of (C) above is subjected to high pressure liquid chromatography to 5 produce oleuropein [Formula I; R = glycosyl; R<sub>1</sub> = 2-(3,4-dihydroxyphenyl)ethyl] and ligstroside [Formula I; R = glycosyl; R<sub>1</sub> = 2-(4-hydroxyphenyl)ethyl] in substantially pure form. The purified oleuropein is formulated alone or in combination with ligstroside with tabletting starch 10 and a tabletting lubricant, magnesium stearate, to form a tabletting mixture. The tabletting mixture is pressed into compressed tablets containing about 30 to about 500 mg of oleuropein per tablet.

15

Example 2

Oleuropein (1 g) is dispersed in 50 ml of methanol. The solution is cooled to about 10°C and treated with stirring with about 2 g of potassium hydroxide pellets. The mixture is allowed to warm to 20 room temperature and after about 6 hours, the reaction mixture is diluted with about 60 ml of 6 N HCl (pH about 7.5) and evaporated to dryness. The chromatographic purification of the product mixture provides oleoside [Formula I; R = glycosyl, R<sub>1</sub> = methyl]. The purified oleoside is formulated into a solid oral dosage form 25 containing about 250 mg of oleoside. Alternatively, oleoside is dissolved in sterile isotonic saline at a concentration of about 5 mg per ml to provide a parenteral dosage form for use in accordance with the 30 method of this invention.

35

Example 3

Five grams of oleuropein is dissolved in 500 ml of water buffered at pH 5.0 and treated with glucosidase until analysis of the reaction mixture by thin layer

-13-

chromatography indicates completion of the reaction. Standard workup of the reaction mixture followed by chromatographic purification of the product mixture provides a compound of Formula II wherein R<sub>1</sub> = 2-(3,4-  
5 dihydroxyphenyl)ethyl. The purified product is formulated into oral or parenteral dosage forms and administered for treatment of viral diseases in accordance with the method of the present invention.

Example 4

10 A solution of 500 mg of the product of Example  
3 in 50 ml of water buffered at about pH 7.5 to about 8.5  
is treated with commercially available esterase at a  
temperature of about 30°C until thin layer  
15 chromatographic analysis of the esterase reaction mixture  
indicates completion of the reaction due to disappearance  
of the starting compound. After reaction completion, the  
pH of the mixture is readjusted to about 8.5 and after  
washing it twice with ethyl acetate, the pH of the  
20 solution is adjusted to about 4.5 in the presence of 30  
ml of ethyl acetate. The ethyl acetate acid extract of  
the reaction mixture is separated, washed with distilled  
water and brine, and dried over anhydrous sodium sulfate.  
Evaporation to dryness provides (+)-elenolic acid  
25 [Formula II; R<sub>1</sub> = hydrogen] in substantially pure form.  
The product is further purified by chromatography and/or  
crystallization as its sodium or potassium salt. It is  
formulated into oral or parenteral dosage forms in  
accordance with this invention for treatment of viral  
30 infections in warm-blooded vertebrates.

Example 5

Dried leaves of *Olea europaea* are ground to a fine powder and loaded into gelatin capsules such that  
35 each capsule contains a volume of ground plant material

-14-

containing between about 30 and about 500 mg of oleuropein per capsule. Dried olive leaves typically contain about 60 to about 90 mg of oleuropein per gram of dried leaf. The capsules are administered orally for  
5 treatment of diseases of viral origin in accordance with this invention.

Example 6


The antiviral efficacy of a composition of  
10 Example 1(A) above was evaluated in treatment of six subjects afflicted with herpes virus infections. Each of the six subjects ingested two ounces of the formulation every six hours. All subjects reported reduction of herpetic lesions. Three subjects reported disappearance  
15 of lesions in 36-48 hours after initiating treatment. One subject, a 34 year old Caucasian female, had several months earlier discontinued use of birth control pills and it was thought that her estrogen surges were causing immunosuppression which complicated her infection. After  
20 three days of doubling the dosage of the tincture (four ounces every six hours) most of her lesions were resolved. Two other subjects, a male and a female, more recently infected were also given the higher doses (four ounces every six hours orally) and each reported  
25 improvement measured by reduction in severity of their herpetic lesions, and in at least one patient, a 22.8% decrease in antibody titers (IgG) three weeks after initiating therapy with the oleuropein-containing olive leaf extract.

-15-


I claim:

1. A method of treatment of disease of viral origin in a warm-blooded vertebrate suffering from such disease, said method comprising the step of administering to said vertebrate an antivirally effective amount of an antiviral composition comprising a compound of the formula

10



(I) or



15

and a pharmaceutically acceptable carrier therefor  
 20 wherein in the above formulas R is glucosyl and R<sub>1</sub> is hydrogen or a pharmaceutically acceptable ester-forming group and when R<sub>1</sub> is hydrogen, the pharmaceutically acceptable salts of the acids represented thereby.

25 2. The method of claim 1 wherein said composition is administered orally.

3. The method of claim 1 wherein said composition is administered parenterally.

4. The method of claim 1 wherein R<sub>1</sub> is 2-(4-hydroxyphenyl)ethyl or 2-(3,4-dihydroxyphenyl)ethyl.

30 5. The method of claim 4 wherein the composition is administered orally.

6. The method of claim 1 wherein the compound is extracted from a plant of the Family Oleaceae.

35 7. The method of claim 6 wherein the antiviral composition is administered orally.


-16-

8. The method of claim 1 wherein the compound is extracted from *Olea europaea*.

9. The method of claim 1 wherein the antiviral composition includes leaves of *Olea europaea* dried, ground and formulated in a solid oral dosage form.

10. A solid oral dosage form for treatment of viral infections in warm-blooded vertebrates, said solid dosage form comprising about 30 to about 500 mg of a compound of the formula

10



and a pharmaceutically acceptable carrier therefor  
20 wherein in the above formulas R is glucosyl and R<sub>1</sub> is hydrogen or a pharmaceutically acceptable ester-forming group and when R<sub>1</sub> is hydrogen, the pharmaceutically acceptable salts of the acids represented thereby.

11. The solid oral dosage form of claim 10 wherein  
25 the compound is extracted from plant material of the  
Family Oleaceae.


12. The solid oral dosage form of claim 10 wherein R<sub>1</sub> is 2-(4-hydroxyphenyl)ethyl or 2-(3,4-dihydroxyphenyl)ethyl.

30        13. The solid oral dosage form of claim 12 wherein  
the antiviral composition includes dried plant material  
of *Olea europaea* or a dried extract thereof.

-17-

14. A method for establishing antivirally effective blood levels of a compound of the formula


5



10 in a warm-blooded vertebrate suffering from a disease of viral origin, said method comprising the step of administering an antiviral composition orally to said vertebrate said composition comprising about 0.1 to about 15 mg/kg of vertebrate body weight of a compound of the

15 formula


20



(I)

or

(II)



and a pharmaceutically acceptable carrier therefor wherein R is glucosyl and R<sub>1</sub> is hydrogen or a pharmaceutically acceptable ester-forming group and when R<sub>1</sub> is hydrogen, pharmaceutically acceptable salts of the acids represented thereby.

15. The method of claim 14 wherein the antiviral composition includes plant material of the Family Oleaceae or a dried extract thereof containing about 0.2 to about 5 mg of the compound/kg of vertebrate body weight.

16. The method of claim 14 wherein the antiviral composition includes an aqueous or aqueous alcoholic extract of *Olea europaea*.

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 31/35

US CL : 514/460

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/460

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category*    | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|--------------|--|-----------------------|
| X<br>--<br>Y | US, A, 3,737,550 (NOOK ET AL) 05 June 1973, see entire document.                   | 1-9<br>-----<br>1-20  |

Further documents are listed in the continuation of Box C.  See patent family annex.

|  |  |
|--|--|
| * Special categories of cited documents: |  |
| "A"                                      | document defining the general state of the art which is not considered to be of particular relevance   |
| "E"                                      | earlier document published on or after the international filing date   |
| "L"                                      | document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) |
| "O"                                      | document referring to an oral disclosure, use, exhibition or other means   |
| "P"                                      | document published prior to the international filing date but later than the priority date claimed   |

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

05 FEBRUARY 1996

Date of mailing of the international search report

01 MAR 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer  
RUSSELL TRAVERS

Telephone No. (703) 308-1235